Biology of osteoclast activation in cancer.

Bone is a frequent site of cancer metastasis. Bone metastases can result in bone destruction or new bone formation. Bone destruction is mediated by factors produced or induced by tumor cells that stimulate formation and activation of osteoclasts, the normal bone-resorbing cells. Local bone destruction also occurs in patients with osteoblastic metastases and may precede or occur simultaneously with increased bone formation. Several factors, including interleukin (IL)-1, IL-6, receptor activator of NF-kappaB (RANK) ligand, parathyroid hormone-related protein (PTHrP), and macrophage inflammatory protein-1-alpha (MIP-1alpha), have been implicated as factors that enhance osteoclast formation and bone destruction in patients with neoplasia. PTHrP seems to be the major factor produced by breast cancer cells that induces osteoclast formation through upregulation of RANK ligand. Enhanced RANK ligand expression also plays an important role in bone destruction in patients with myeloma. RANK ligand can act to enhance the effects of other factors produced by myeloma cells or in response to myeloma cells, such as MIP-1alpha and/or IL-6, to induce osteoclast formation. Understanding of the molecular mechanisms responsible for osteoclast activation in osteolytic metastases should lead to development of novel therapeutic approaches for this highly morbid and potentially fatal complication of cancer.

[1]  G D Roodman,et al.  Cell biology of the osteoclast. , 1999, Experimental hematology.

[2]  K Yano,et al.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.

[3]  R. Bataille,et al.  Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. , 1997, Blood.

[4]  R. Bataille,et al.  Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. , 1999, Journal of immunology.

[5]  J. Warwick,et al.  Parathyroid hormone related protein and skeletal morbidity in breast cancer. , 1992, European journal of cancer.

[6]  T. Martin,et al.  Osteoblastic cells are involved in osteoclast formation. , 1988, Endocrinology.

[7]  H. Saisho,et al.  Significance of parathyroid hormone‐related protein as a factor stimulating bone resorption and causing hypercalcemia in myeloma , 1998, American journal of hematology.

[8]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[9]  G. Mundy,et al.  Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[10]  E. Ogata,et al.  Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. , 2000, Biochemical and biophysical research communications.

[11]  G. Roodman,et al.  Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. , 2001, Blood.

[12]  B. Klein,et al.  Mechanisms of bone lesions in multiple myeloma. , 1992, Hematology/oncology clinics of North America.

[13]  T. Bringman,et al.  Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. , 1987, The New England journal of medicine.

[14]  J. M. Jennings,et al.  Carbonic Anhydrase and Bone Remodeling: Sulfonamide Inhibition of Bone Resorption in Organ Culture , 1972, Science.

[15]  T. Suda,et al.  IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. , 1990, Journal of immunology.

[16]  M. Koizumi,et al.  Correlation between bone metabolic markers and bone scan in prostatic cancer. , 1997, The Journal of urology.

[17]  F. Craig,et al.  Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. , 2000, Blood.

[18]  R. Rubens,et al.  The clinical course of bone metastases from breast cancer. , 1987, British Journal of Cancer.

[19]  A. Waage,et al.  Hepatocyte Growth Factor (HGF) Induces Interleukin-11 Secretion From Osteoblasts: A Possible Role for HGF in Myeloma-Associated Osteolytic Bone Disease , 1999 .

[20]  G. Lyman,et al.  High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. , 1994, Blood.

[21]  P. Lansdorp,et al.  Production of interleukin-1 by bone marrow myeloma cells , 1989 .

[22]  J. Epstein,et al.  Myeloma phenotype: clues to disease origin and manifestation. , 1992, Hematology/oncology clinics of North America.

[23]  M. Obinata,et al.  Establishment and characterization of bone marrow stromal cell lines that support osteoclastogenesis. , 1995, Endocrinology.

[24]  L. Hofbauer,et al.  Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. , 1998, European journal of endocrinology.

[25]  T. Ohta,et al.  Serum pyridinoline crosslinks as markers of tumour-induced bone resorption. , 1997, British journal of urology.

[26]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Ogata,et al.  Clinical significance of interleukin-6 gene expression in the bone marrow of patients with multiple myeloma. , 1999, International journal of hematology.

[28]  M. Jourdan,et al.  Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. , 1989, The Journal of clinical investigation.

[29]  A. Zallone,et al.  Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts. , 2000, Biochemical and biophysical research communications.

[30]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[31]  P. Croucher,et al.  Expression of interleukin‐1β and tumour necrosis factor‐α in plasma cells from patients with multiple myeloma , 1999 .

[32]  N. Kugai,et al.  The Mouse Mammary Tumor Cell Line, MMT060562, Produces Prostaglandin E2 and Leukemia Inhibitory Factor and Supports Osteoclast Formation In Vitro Via a Stromal Cell–Dependent Pathway , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  G. Mundy,et al.  Direct resorption of bone by human breast cancer cells in vitro , 1978, Nature.

[34]  S. Adami.  Bisphosphonates in prostate carcinoma , 1997, Cancer.

[35]  T. Chambers,et al.  Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. , 1999, Endocrinology.

[36]  N. Udagawa,et al.  Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. , 1998, Biochemical and biophysical research communications.

[37]  G. Ahmann,et al.  Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. , 1999, Blood.

[38]  E. Chen,et al.  A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. , 1987, Science.

[39]  A. Boyde,et al.  Scanning electron microscopy in bone pathology: review of methods, potential and applications. , 1986, Scanning electron microscopy.

[40]  R. Warrell,et al.  Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. , 1990, The New England journal of medicine.

[41]  C. Gay,et al.  Ultrastructural immunocytochemical localization of carbonic anhydrase in normal and calcitonin‐treated chick osteoclasts , 1982, The Anatomical record.

[42]  J. Rossi,et al.  Interleukin‐1 in multiple myeloma: producer cells and their role in the control of IL‐6 production , 1998, British journal of haematology.

[43]  G. Roodman,et al.  Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. , 1997, Cancer research.

[44]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[45]  J. Magaud,et al.  Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma. , 1998, Leukemia & lymphoma.

[46]  B F Boyce,et al.  Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. , 1996, The Journal of clinical investigation.

[47]  K. Anderson,et al.  Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. , 1997, Hematology/oncology clinics of North America.

[48]  C. Löwik,et al.  Effects of experimental conditions on the release of 45calcium from prelabeled fetal mouse long bones. , 1995, Bone.

[49]  A. F. Stewart,et al.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. , 1980, The New England journal of medicine.

[50]  G. Mundy,et al.  Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. , 1991, Endocrinology.

[51]  J. Lust,et al.  THE ROLE OF INTERLEUKIN-1β IN THE PATHOGENESIS OF MULTIPLE MYELOMA , 1999 .

[52]  B. Klein,et al.  Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. , 1995, Blood.

[53]  G. Ciliberto,et al.  IL‐6 Mediates the Effects of IL‐1 or TNF, but Not PTHrP or 1,25(OH)2D3, on Osteoclast‐like Cell Formation in Normal Human Bone Marrow Cultures , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[54]  D. Hewett‐Emmett,et al.  Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. , 1985, The New England journal of medicine.

[55]  T. Martin,et al.  The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. , 1989, Endocrinology.

[56]  C. Chenu,et al.  Interleukin‐1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[57]  S. Niida,et al.  BriefDefinitive Report Essential Role of Macrophage Colony-Stimulating Factor in the Osteoclast Differentiation Supported by , 2022 .

[58]  G. Roodman,et al.  Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. , 1995, The Journal of clinical investigation.

[59]  M. Oursler,et al.  Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. , 1999, Cancer research.

[60]  H. Asaoku,et al.  Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. , 1989, Blood.

[61]  S. Teitelbaum,et al.  Osteoclastic bone resorption by a polarized vacuolar proton pump. , 1989, Science.

[62]  J. Hayman,et al.  Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. , 1990, Cancer research.

[63]  Paul J. Williams,et al.  Cell–cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity , 2000 .

[64]  R. L. Cain,et al.  Comparison of Recombinant Human PTH(1–34) (LY333334) with a C‐Terminally Substituted Analog of Human PTH‐Related Protein(1–34) (RS‐66271): In Vitro Activity and In Vivo Pharmacological Effects in Rats , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[65]  G. Roodman,et al.  Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice. , 1989, Endocrinology.

[66]  T. Martin,et al.  Parathyroid hormone‐related protein in hypercalcaemia associated with haematological malignancy , 1996, British journal of haematology.